ArticleJournal of innate immunity2012
Alveolar macrophage cathelicidin deficiency in severe sarcoidosis.
Article in Journal of innate immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Calcium, Phosphate, and Vitamin D Status in Patients with Sarcoidosis-Associations with Disease Activity and Symptoms.Journal of clinical medicine · 2023Article
- A transcriptomics-based meta-analysis identifies a cross-tissue signature for sarcoidosis.Frontiers in medicine · 2022Article
- Application of Proteomics in Sarcoidosis.American journal of respiratory cell and molecular biology · 2020Review
- The role of vitamin D in sarcoidosis.Faculty reviews · 2020Review
- Cathelicidin Contributes to the Restriction ofFrontiers in immunology · 2019Article
- Vitamin D status in sarcoidosis: a cross-sectional study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Transcriptome profiles in sarcoidosis and their potential role in disease prediction.Current opinion in pulmonary medicine · 2017Review
- TREM-2 Receptor Expression Increases with 25(OH)D Vitamin Serum Levels in Patients with Pulmonary Sarcoidosis.Mediators of inflammation · 2015Article
- Inflammation and vitamin D: the infection connection.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2014Review
- The Janus face of macrophages in immunity.Journal of innate immunity · 2014Article
- Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease.Journal of immunology (Baltimore, Md. : 1950) · 2013Review
- Macrophages: past, present and future.Journal of innate immunity · 2013Article
- Sarcoidosis and calcium homeostasis disturbances-Do we know where we stand?Chronic respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDysfunctional immune responses characterize sarcoidosis, but the status of cathelicidin, a potent immunoregulatory and antimicrobial molecule, has not been established in clinical disease activity.
methodsAlveolar macrophage cathelicidin expression was determined in biopsy-proven sarcoidosis patients classified clinically as 'severe' (requiring systemic treatment) or 'non-severe' (never requiring treatment). Bronchoalveolar lavage (BAL) cells from sarcoidosis patients and healthy controls were analyzed for mRNA expression of cathelicidin, vitamin D receptor (VDR) and the VDR coactivator steroid receptor coactivator-3 (SRC3) by quantitative PCR. Cathelicidin-derived peptide LL-37 was determined by immunocytochemistry. Serum calcidiol (25-hydroxyvitamin D2; vitD2) and calcitriol (1,25-dihydroxyvitamin D3; vitD3) were quantified.
resultsThe results indicated reduced BAL cell expression of cathelicidin and SRC3 in severe but not non-severe sarcoidosis compared to controls. Serum levels of biologically active vitD3 in both severe and non-severe patients were within the control range even though vitD2 levels in both groups were below the recommended level (30 ng/ml). Sarcoidosis and control alveolar macrophages were studied in vitro to determine cathelicidin responses to vitD3 and tumor necrosis factor-α (TNFα), a vitD3 antagonist elevated in active sarcoidosis. Alveolar macrophage cathelicidin was stimulated by vitD3 but repressed by TNFα, which also repressed SRC3.
conclusionsThese findings suggest that TNFα-mediated repression of SRC3 contributes to alveolar macrophage cathelicidin deficiency in severe sarcoidosis despite healthy vitD3 levels. Deficiency of cathelicidin, a multifunctional regulator of immune cells and proinflammatory cytokines, may impede resolution of inflammation in the lungs of patients with severe sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.